Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430495 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
A Phase 2 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 2
- Development phase
- 256
- Enrollment target
NCT00430495 is a Phase 2 study that has completed, run by EMD Serono. The registered enrollment target is 256 participants.
The verdict
NCT00430495, a Phase 2 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 256 participants
- Enrollment target
Study Summary
This was a double-blind, placebo-controlled, parallel-arm, multicentre, prospective dose-finding trial of the safety and efficacy of atacicept in subjects with active rheumatoid arthritis who had failed a three month therapeutic trial with a tumor necrosis factor alpha (TNFa) antagonist due to lack of efficacy.
Interventions
- DRUG Atacicept
- DRUG Placebo matched to atacicept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00430495
The ClinicalTrials.gov registry entry for NCT00430495 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atacicept is the first listed.
NCT00430495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00430495 about?
NCT00430495 is a clinical study titled "A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)". This was a double-blind, placebo-controlled, parallel-arm, multicentre, prospective dose-finding trial of the safety and efficacy of atacicept in subjects with active rheumatoid arthritis who had failed a three month therapeutic trial with a tumor necrosis factor alpha (TNFa) antagonist due to lack ...
What is the current status of trial NCT00430495?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2006-12. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00430495?
The interventions under investigation include: Atacicept (DRUG), Placebo matched to atacicept (DRUG).
Who is sponsoring clinical trial NCT00430495?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.